NCT04123704View on ClinicalTrials.gov

Sitravatinib in Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

January 22, 2023

Study Completion Date

January 22, 2023

Conditions

Breast Cancer Stage IVTriple Negative Breast CancerBreast NeoplasmsBreast Cancer Metastatic

Interventions

DRUG

Sitravatinib

sitravatinib capsule

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

Mirati Therapeutics Inc.

All Listed Sponsors

collaborator

Mirati Therapeutics Inc.

INDUSTRY

lead

Xiang Zhang

OTHER

NCT04123704 - Sitravatinib in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter